Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
14.07
+0.11 (0.79%)
Nov 4, 2024, 12:44 PM EST - Market open
Takeda Pharmaceutical Employees
Takeda Pharmaceutical Company had 49,281 employees as of March 31, 2024. The number of employees increased by 186 or 0.38% compared to the previous year.
Employees
49,281
Change (1Y)
186
Growth (1Y)
0.38%
Revenue / Employee
$643,904
Profits / Employee
$41,075
Market Cap
44.26B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | 47,495 | -2,083 | -4.20% |
| Mar 31, 2019 | 49,578 | 22,348 | 82.07% |
| Mar 31, 2018 | 27,230 | -2,670 | -8.93% |
| Mar 31, 2017 | 29,900 | -1,268 | -4.07% |
| Mar 31, 2016 | 31,168 | -160 | -0.51% |
| Mar 31, 2015 | 31,328 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| CVS Health | 300,000 |
| IQVIA Holdings | 87,000 |
| Becton, Dickinson and Company | 73,000 |
| McKesson | 51,000 |
| GE HealthCare Technologies | 51,000 |
| Cencora | 46,000 |
| Haleon | 25,408 |
| Alcon | 25,315 |
TAK News
- 3 days ago - Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments - Reuters
- 4 days ago - Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook - Business Wire
- 11 days ago - Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem - Business Wire
- 4 weeks ago - Takeda Pharmaceuticals: An Interesting Option For Income Investors - Seeking Alpha
- 5 weeks ago - Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development - Business Wire
- 5 weeks ago - Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer - Business Wire
- 6 weeks ago - Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024 - Business Wire